These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1339916)

  • 1. Relationship between the dose and whole blood level of cyclosporine after liver and kidney transplantation.
    Kahn D; Cervio G; Mazzaferro V; Venkataramanan R; Makowka L; Van Thiel DH; Starzl TE
    J Clin Lab Immunol; 1992; 37(4):163-71. PubMed ID: 1339916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Living donor liver transplant recipients achieve relatively higher immunosuppressant blood levels than cadaveric recipients.
    Trotter JF; Stolpman N; Wachs M; Bak T; Kugelmas M; Kam I; Everson GT
    Liver Transpl; 2002 Mar; 8(3):212-8. PubMed ID: 11910565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of cyclosporine level at 2 hours after administration in preoperative kidney transplant recipients for prediction of postoperative optimal cyclosporine dose.
    Sukhavasharin N; Praditpornsilpa K; Avihingsanon Y; Kuoatawintu P; O-Charoen R; Kansanabuch T; Tungsanga K; Eiam-Ong S
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S15-20. PubMed ID: 17044449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Six-month clinical outcome of cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients previously maintained on sandimmun neoral.
    Al Wakeel JS; Shaheen FA; Mathew MC; Abou Zeinab HM; Al Alfi A; Tarif NM; Al Mousawi MS; Mahmoud TS; Alorrayed AS; Fagir EA; Dham RS; Shaker DS
    Transplant Proc; 2008 Sep; 40(7):2245-51. PubMed ID: 18790205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of adverse reactions to cyclosporine after liver transplantation is predicted by the first blood level.
    Azoulay D; Lemoine A; Dennison A; Gries JM; Dolizy I; Castaing D; Beaune P; Bismuth H
    Hepatology; 1993 Jun; 17(6):1123-6. PubMed ID: 8514263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.
    Simonson SG; Raza A; Martin PD; Mitchell PD; Jarcho JA; Brown CD; Windass AS; Schneck DW
    Clin Pharmacol Ther; 2004 Aug; 76(2):167-77. PubMed ID: 15289793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C2 monitoring in maintenance renal transplant recipients: is it worthwhile?
    Midtvedt K; Fauchald P; Bergan S; Høieggen A; Hallan S; Svarstad E; Bergrem H; Eriksen BO; Pfeffer PF; Dalen I; Leivestad T
    Transplantation; 2003 Oct; 76(8):1236-8. PubMed ID: 14578761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cyclosporin interactions in kidney transplants].
    Díaz Couselo FA; Porato F; Turín M; Etchegoyen FP; Diez RA
    Medicina (B Aires); 1992; 52(4):296-302. PubMed ID: 1340878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus.
    Bäckman L; Reisaeter AV; Wramner L; Ericzon BG; Salmela K; Brattström C
    Clin Transplant; 2006; 20(3):336-9. PubMed ID: 16824151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-years experience with Neoral C2 monitoring adjusted to a target range of 500-600 ng/ml in long-term renal transplant recipients receiving dual immunosuppressive therapy.
    Carstens J
    Scand J Urol Nephrol; 2008; 42(3):286-92. PubMed ID: 18432535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients.
    Jain AK; Venkataramanan R; Shapiro R; Scantlebury VP; Potdar S; Bonham CA; Ragni M; Fung JJ
    Liver Transpl; 2002 Sep; 8(9):841-5. PubMed ID: 12200788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
    Büchler M; Chadban S; Cole E; Midtvedt K; Thervet E; Prestele H; Keown P
    Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ideal therapeutic range of cyclosporine in whole blood in kidney-transplanted patients.
    Xu F; Chen ZL; Jin WJ; Xie QD; Shi XH
    Int J Clin Pharmacol Res; 1993; 13(4):221-4. PubMed ID: 8150548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Conversion from +Sandimmune to Neoral in kidney transplant recipients treated with cyclosporine and ketoconazole].
    Videla C; Vega J; Borja H; Gatica A; Clavero R; Aldunate T
    Rev Med Chil; 1997 Apr; 125(4):438-45. PubMed ID: 9460285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study.
    Stock PG; Roland ME; Carlson L; Freise CE; Roberts JP; Hirose R; Terrault NA; Frassetto LA; Palefsky JM; Tomlanovich SJ; Ascher NL
    Transplantation; 2003 Jul; 76(2):370-5. PubMed ID: 12883195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C2 is an age-independent parameter for optimal cyclosporine exposure in long-term kidney transplant recipients.
    Ferraresso M; Citterio F; Ghio L; Romagnoli J; Edefonti A; Berardinelli L; Castagneto M
    Transplant Proc; 2004 Nov; 36(9):2656-8. PubMed ID: 15621115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
    Kovarik JM; Kahan BD; Kaplan B; Lorber M; Winkler M; Rouilly M; Gerbeau C; Cambon N; Boger R; Rordorf C;
    Clin Pharmacol Ther; 2001 Jan; 69(1):48-56. PubMed ID: 11180038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome after cyclosporine dose reduction based on C2 levels in long-term liver transplant patients.
    Tha-In T; Hesselink DA; Tilanus HW; Elshove L; Wilschut AL; Hansen BE; van Gelder T; Metselaar HJ
    Clin Transplant; 2005 Aug; 19(4):537-42. PubMed ID: 16008602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection.
    Sandborn WJ; Hay JE; Porayko MK; Gores GJ; Steers JL; Krom RA; Wiesner RH
    Hepatology; 1994 Apr; 19(4):925-32. PubMed ID: 8138267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total cholesterol correlates with cyclosporine C2 levels in kidney transplant recipients under maintenance immunosuppression.
    Cardinal H; Barama AA; Fradet V; Lallier M; Lévesque R; St Louis G; Hébert MJ; Girardin C; Pâquet M; Daloze P
    Transplant Proc; 2004 Mar; 36(2 Suppl):448S-450S. PubMed ID: 15041384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.